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Personalised medicine strives to identify the right treatment for the right
patient at the right time, integrating different types of biological and environ-
mental information. Such information come from a variety of sources: omics
data (genomic, proteomic, metabolomic, etc.), live molecular diagnostics, and
other established diagnostics routinely used by medical doctors [6]. Integrating
these different kinds of data, which are all high-dimensional, presents significant
challenges in knowledge representation and subsequent reasoning [4, 18]. The
ultimate goal of such a modelling effort is to elucidate the flow of information
that links genes, protein signalling and other physiological responses to external
stimuli such as environmental conditions or the progress of a disease.
Omics data, which include single-nucleotide polymorphisms (SNPs), protein
and gene regulatory networks, are investigated using high-throughput platforms
such as the ones developed for the Human Genome project [2, 14]. Systems biol-
ogy studies the relationships among the elements in omics data as they change in
the presence of genetic and environmental perturbations, extending techniques
that were previously used on a smaller scale [13]. Such knowledge can improve
our ability to understand and predict the behaviour of complex biological sys-
tems, but requires careful handling in integrating different sources. On its own,
each type of data often contains too much noise for single biological signals to be
identifiable, much less their interplay. Pooling the information available across
omics data (e.g. sequencing and expression information about relevant genes,
possibly under different treatment regimens) provides an option to increase sta-
tistical power and produce reliable knowledge representation models [10].
The role of live molecular diagnostics, and to some extent of traditional
diagnostics, is to complement omics data with longitudinal measures of the pa-
tient’s condition that are easier and cheaper to collect. Several examples of the
modelling and implementation techniques involved are covered in the previous
sections. Integrating such diagnostics is essential because genetic information
correlate only imperfectly with protein levels [8], which in turn are very noisy
predictors of most pathologies.
Applications of personalised medicine fall roughly in three groups. Firstly,
drug discovery and development can be made more efficient and effective [6]. On
the one hand, omics data can provide feedback at early stages of drug discovery
by replacing the traditional trial-and-error approach with a hypothesis-driven
one based on a formal knowledge representation model. On the other hand,
omics data can also be used to improve clinical trial design by guiding patients
selection and stratification based on predicted drug toxicity and non-responders
profiles. This is likely to prove more effective than defining populations in terms
of race or ethnicity, since only 5−10% of the total human genetic variance occurs
between different ethnic groups [1] and boundaries between different populations
are often not clear.
Secondly, several aspects of the diagnostic process can be improved. For ex-
ample, the normal behaviour of a biological system can be better defined at the
molecular level than using non-specific clinical signs. As a result, pathologies can
be classified with greater precision based on a molecular taxonomy [6]; previously
unknown differences have been highlighted in breast cancer [7] and leukaemia
[17] in this way. Furthermore, genetic tests need to be improved in their sen-
sitivity and specificity; they are challenging to perform reliably and interpret
correctly, and they focus predominantly on rare diseases [9].
Thirdly, personalised medicine allows treatment for many diseases to be tai-
lored to each patient to an unprecedented degree. For example, adverse reac-
tions to specific compounds can be predicted with greater accuracy, and non-
responders can be identified without actually starting a therapy that may or
may not be effective.
To investigate and implement personalised medicine in practice, many chal-
lenges need to be overcome at the modelling level; some of them will be covered
in the following chapter. First and foremost, a working knowledge representation
model must be established to facilitate reasoning on high-dimensional, hetero-
geneous data. Currently, probabilistic graphical models (Bayesian networks in
particular) seem to be a popular approach [3, 5, 12]. Their ability to provide at
the same time an intuitive understanding of the data to biologists and medical
doctors (through the graph structure) and a rigorous probabilistic framework to
statisticians and computer scientists makes them an ideal tool for this task.
Moreover, specific distributional assumptions are required to accurately de-
scribe both omics and diagnostics data effectively. Gaussian and discrete Bayesian
networks from classic literature [16] present important limitations in modelling
omics data, as do more general models such as chain graphs. For instance, as-
suming normality for gene expressions will almost certainly result in a biased
model, because expression levels are usually highly skewed. Likewise, ignoring
the ordering of the alleles in SNP data disregards information which is known
to be fundamental in quantitative genetics. Ideally, probabilistic assumptions
should also support the inclusion of available prior information from different
sources, as in Schadt et al. [15].
A related issue is the computational complexity of both model estimation
and subsequent inference, which poses severe limits to the use of flexible dis-
tributional assumptions in Bayesian networks and to the scope of the questions
these networks can answer. The use of prior information can speed up model
estimation by reducing the set of the models under consideration, even though
it may introduce bias as well if the phenomenon we are modelling is not well
understood. Another possible solution is to perform feature selection as a pre-
processing step, thus speeding up inference as well. In the context of Bayesian
networks, Markov blankets provide a natural way to do so while retaining as
much information as possible [11]. However, given the complexity of the data
used in personalised medicine, the cost of feature selection is often as high as
that of model estimation.
In conclusion, while there are many open problems to address, an effective
use of knowledge representation is crucial in implementing reliable personalised
medicine protocols. Omics and other established diagnostics provide a wealth of
data, which calls for appropriate modelling spanning techniques from statistics,
computer science and quantitative biology.
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